Re-challenge with pemetrexed in advanced mesothelioma: A multi-institutional experience

BMC Research Notes

Volumn 5, Issue , 2012, Pages

  Bearz, Alessandra ^a   Talamini, Renato ^a   Rossoni, Gilda ^b   Santo, Antonio ^c   De Pangher, Vincenzo ^d   Fasola, Gianpiero ^e   Rosetti, Francesco ^c   Favaretto, Adolfo ^f   Gregorc, Vanesa ^b   Berretta, Massimiliano ^a   Santarossa, Sandra ^a   Berto, Eleonora ^a   Tirelli, Umberto ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b Medical Oncology   (Italy)

^c GENERAL HOSPITAL   (Italy)

^d General Hospital   (Italy)

^e UNIVERSITY HOSPITAL OF UDINE   (Italy)

^f VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE; PEMETREXED;

ARTICLE; FEMALE; HUMAN; MALE; MESOTHELIOMA; MULTICENTER STUDY; PLEURA TUMOR; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; FEMALE; GLUTAMATES; GUANINE; HUMANS; MALE; MESOTHELIOMA; PLEURAL NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84865598518     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-5-482     Document Type: Article

References (25)

1. Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia. Lee CW, Murray N, Anderson H, Rao SC, Bishop W, Lung Cancer 2009 64 308 313 10.1016/j.lungcan.2008.09.008 19004520
2. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. Byrne M, Davidson J, Musk A, Dewar J, van Hazel G, Buck M, J Clin Oncol 1999 17 25 30 10630258
3. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Nowak A, Byrne M, Williamson R, Ryan G, Segal A, Fielding D, Br J Cancer 2002 87 491 496 10.1038/sj.bjc.6600505 12189542
4. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. Vogelzang N, Rusthoven J, Symanowski J, Denham C, Kaukel E, Ruffie P, J Clin Oncol 2003 21 2636 2644 10.1200/JCO.2003.11.136 12860938
5. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of European Organisation for Reasearch and Treatment of Cancer Lung Cancer Group and National Cancer Institute of Canada. Van Meerbeck J, Gaafar R, Manegold C, Van Klaveren R, Van Marck E, Vincent M, J Clin Oncol 2005 23 6681 6689
6. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non small-cell lung cancer: an individual patient data meta-analysis. Ardizzoni A, Boni L, Tiseo M, Fossella F, Schiller J, Paesmans M, J Natl Cancer Inst 2007 99 847 857 10.1093/jnci/djk196 17551145
7. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. Hughes A, Calvert P, Azzabi A, Plummer R, Johnson R, Rusthoven J, J Clin Oncol 2002 20 3533 3544 10.1200/JCO.2002.10.073 12177114
8. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. Ceresoli G, Zucali P, Favaretto A, Grossi F, Bidoli P, Del Conte G, J Clin Oncol 2006 24 1443 1448 10.1200/JCO.2005.04.3190 16549838
9. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicenter phase II study. Favaretto A, Aversa S, Paccagnella A, Vde Manzini P, Palmisano V, Oniga F, Cancer 2003 97 2791 2793 10.1002/cncr.11405 12767092
10. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. Byrne MJ, Davidson JA, Musk AW, Dewar J, von Hazel G, Buck M, J Clin Oncol 1999 17 25 30 10630258
11. Open-label study of pemetrexed alone in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Janne PA, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Clin Lung Cancer 2005 7 40 46 10.3816/CLC.2005.n.020 16098243
12. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program. Janne PA, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, J Thor Oncol 2006 1 506 512 10.1097/01243894-200607000-00002
13. Phase III Trial of Pemetrexed Plus Best Supportive Care Compared With Best Supportive Care in Previously Treated Patients With Advanced Malignant Pleural Mesothelioma. Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S, Blatter J, Adachi S, Hanauske A, Manegold C, J Clin Oncol 2008 26 1698 1704 10.1200/JCO.2006.09.9887 18375898
14. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. Steele JP, Shamash J, Evans MT, Gower NH, Tischkowitz MD, Rudd RM, J Clin Oncol 2000 18 3912 3917 11099320
15. Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: A multi-institutional retrospective analysis. Garassino MC, Torri V, Michetti G, Lo Dico M, La Verde N, Aglione S, Mancuso A, Gallerani E, Galetta D, Martelli O, Collovà E, Lung Cancer 2011 2011 72 378 383
16. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Byrne MJ, Nowak K, Ann Oncol 2004 15 257 260 10.1093/annonc/mdh059 14760119
17. Prediction of creatinine clearance from serum creatinine. Cockcroft DW, Gault MH, Nephron 1976 16 31 41 10.1159/000180580 1244564
18. Non-parametric estimation from incomplete observations. Kaplan EL, Meier P, J Am Stat Assoc 1958 53 457 481 10.1080/01621459.1958.10501452
19. Measurement of pain. Huskisson EC, Lancet 1974 2 1127 1131 4139420
20. Clinical applications of visual analogue scales: a critical review. Mccormack HM, Horne DJ, Sheather S, Psychol Med 1988 18 1007 1119 10.1017/S0033291700009934 3078045
21. Second-line therapy in patients with malignant pleural mesothelioma. A French retrospective study (2005-2006). Margery J, Riviere F, Planchard D, Le Floch H, Ferrand FR, Mairovitz A, Besse B, Vaylet F, Ruffie P, Rev Pneumol Clin 2010 66 255 259 10.1016/j.pneumo.2010.07.013 20933167
22. Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: A mono-institutional experience. Pasello G, Nicotra S, Marulli G, Rea F, Bonanno L, Carli P, Magro C, Jirillo A, Favaretto A, Lung Cancer 2011 73 351 355 10.1016/j.lungcan.2011.01.005 21296448
23. Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma. Schramm A, Opitz I, THies S, Seifert B, Moch H, Weder B, Soltermann A, Eur J Cardiothorac Surg. 2010 37 566 572 10.1016/j.ejcts.2009.08. 027 19781955
24. Predictive and prognostic factors in malignant pleural mesothelioma. Baas P, Curr Opin Oncol 2003 15 127 130 10.1097/00001622-200303000-00002 12601276
25. Retreatment with pemetrexed based chemotherapy in patients with malignant pleural mesothelioma. Ceresoli G, Zucali PA, De Vincenzo F, Gianoncelli L, Simonelli M, Lorenzi E, Ripa C, Giordano L, Santoro A, Lung Cancer 2011 72 73 77 10.1016/j.lungcan.2010.12.004 21216487